6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Point-of-Care Testing of Coagulation in Patients Treated With Non-Vitamin K Antagonist Oral Anticoagulants.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Specific coagulation assays for non-vitamin K antagonist oral anticoagulants (NOAC) are relatively slow and often lack availability. Although specific point-of-care tests (POCT) are currently not available, NOAC are known to affect established coagulation POCT. This study aimed at determining the diagnostic accuracy of the CoaguChek POCT to rule out relevant concentrations of rivaroxaban, apixaban, and dabigatran in real-life patients.

          Related collections

          Author and article information

          Journal
          Stroke
          Stroke; a journal of cerebral circulation
          1524-4628
          0039-2499
          Oct 2015
          : 46
          : 10
          Affiliations
          [1 ] From the Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research (M.E., C.S., F.H., M.W., N.W., F.R., U.Z., S.P.), Division of Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine IV (A.P.), Department of Cardiology and Cardiovascular Medicine (C.S.Z.), and Department of Clinical Epidemiology and Applied Biometry (G.B.), University of Tübingen, Tübingen, Germany; and Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center, Bad Oeynhausen, Ruhr University, Bochum, Germany (I.B., J.K.).
          [2 ] From the Department of Neurology and Stroke, and Hertie Institute for Clinical Brain Research (M.E., C.S., F.H., M.W., N.W., F.R., U.Z., S.P.), Division of Clinical Chemistry and Pathobiochemistry, Department of Internal Medicine IV (A.P.), Department of Cardiology and Cardiovascular Medicine (C.S.Z.), and Department of Clinical Epidemiology and Applied Biometry (G.B.), University of Tübingen, Tübingen, Germany; and Institute for Laboratory and Transfusion Medicine, Heart and Diabetes Center, Bad Oeynhausen, Ruhr University, Bochum, Germany (I.B., J.K.). sven.poli@uni-tuebingen.de.
          Article
          STROKEAHA.115.010148
          10.1161/STROKEAHA.115.010148
          26272385
          a8f7d369-39b7-4678-80d3-3792640611b6
          © 2015 American Heart Association, Inc.
          History

          apixaban,dabigatran,rivaroxaban,stroke,thrombolytic therapy
          apixaban, dabigatran, rivaroxaban, stroke, thrombolytic therapy

          Comments

          Comment on this article